The end of the experiment will now be driven by the authorization and sale of cannabis-based medicines by health authorities. ; however, the final deadline was set: December 31, 2024.
In this experimental context (which can no longer accept new participants as of March 27, 2024) some patients were able to benefit from innovative treatment. Indications? They are precise: persistent neuropathic pain despite conventional treatment; specific drug-resistant forms of epilepsy; persistent oncological symptoms associated with cancer or its treatment.
When this pilot project began with the first patient, no one imagined that three years later – the threshold for its completion – it would be extended. This decision is intended to ensure continuity of care for those already participating in this clinical trial. Therefore, they remain the only ones who benefit from the prescriptions and supplies of these specific treatments.
It is important to note that these requirements are currently subject to revision. temporary authorization issued by the National Agency for the Safety of Medicines (ANSM). And to make life even easier for the patients involved, their purchases are covered by health insurance until the end of the program.
As for interested patients… They are fully informed: they are informed of specific precautions for use, warned of possible side effects and aware of contraindications. All of this is intended to provide a safe and informed foundation for those navigating these uncharted waters of medical cannabis.
Source
Related Posts
National Malaria Program (PNLP) press conference: Coordinator calls for greater stakeholder participation in eliminating malaria by 2030.
Air pollution harms mental health, US study finds
